Interleukin-1-beta - Immunex/Roche

Drug Profile

Interleukin-1-beta - Immunex/Roche

Alternative Names: Interleukin-1-beta - Immunex

Latest Information Update: 18 Oct 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Roche Palo Alto LLC
  • Class Interleukins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Granulocyte macrophage colony stimulating factor agonists; Interleukin 1 stimulants; Macrophage colony stimulating factor stimulants; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Chemotherapy-induced damage; Gastrointestinal cancer; Malignant melanoma; Myeloid leukaemia; Radiation injuries; Renal cancer

Most Recent Events

  • 18 Oct 2000 No-Development-Reported for Chemotherapy induced damage (Prevention)/Chemoprotection in USA (IV-infusion)
  • 18 Oct 2000 No-Development-Reported for Gastrointestinal cancer in USA (IV-infusion)
  • 18 Oct 2000 No-Development-Reported for Malignant melanoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top